Animal Vaccines Market Research Report - Global Forecast till 2030

Animal Vaccines Market: Information by Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Companion Animal Vaccines and Aquacultutre Vaccines), By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, And Others), and By Region (Americas, Europe, Asia-Pacific, Middle East, & Africa)—Forecast to 2030

ID: MRFR/HC/5718-CR | March 2022 | Region: Global | 169 Pages         

Animal Vaccines Market Speak to Analyst Request a Free Sample

Animal Vaccines Market

Animal Vaccines Market is expected to reach USD 15250.5 Million at CAGR of 7.50 % during the forecast period of 2022-2030

By Type Porcine Vaccines Poultry Vaccines Livestock Vaccines Companion Animal Vaccines Aquacultutre Vaccines
By Technology Live Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Recombinant Vaccines Others
By Region Americas Europe Asia-Pacific Middle East& Africa
Key Players
Companies Profiled   Boehringer Ingelheim International GmbH (Germany)   Zoetis Inc. (US)   Ceva SantĂ© Animale (France)   Merck & Co. Inc. (US)   Elanco Animal Health Incorporated (US)   Virbac (France)   Phibro Animal Health Corporation (US)   Hipra (Spain)   BiogĂ©nesis BagĂł S.A.(Argentina)   Neogen Corporation (US)
Market Driving Forces   Rising zoonotic and chronic diseases in animals   Increasing emphasis on animal healthcare and vaccination
Request a Free Sample

Animal Vaccines Market Overview

Animal Vaccines Market registering a CAGR of 7.50% during the forecast period (2020 - 2030), The market was valued at USD 8,013.06 million in 2020 and expected to reach USD 15250.5 million by 2030.

Animal vaccines market study includes market size analysis and a detailed analysis of the manufacturer’s products and service strategies. The growth of the global animal vaccines market is expected to be driven by the rising zoonotic & chronic diseases in animals and increasing emphasis on animal healthcare and vaccination. However, high storage costs associated with vaccines and stringent regulatory guidelines is restraining factor for the animal vaccines market. On the other hand, growth in the number of products launched to immunize various species is favoring the growth in the animal vaccines market.

September 2022

In a move that can strengthen India’s resolve to eliminate human rabies deaths transmitted by dogs by 2030, Ahmedabad-based Cadila Pharmaceuticals is working on rabies vaccines that are effective with fewer doses than the current five-dose regime. The company has recently launched the world’s first three-dose rabies vaccine and is working on developing a single-dose vaccine.

While conventional rabies vaccines are administered five times over a period of 28 days, Cadila’s vaccine dosage schedule is completed within a week (on day zero, third day and seventh day).

COVID-19 Analysis:

The COVID-19 pandemic has impacted the animal vaccines market significantly due to several factors such as a decline in demand, abandoning pets, and restrictions levied by government authorities, among others. Veterinary hospitals and clinics had to undergo several changes to cope with the restrictions faced by the pandemic, such as wearing PPE kits, maintaining social distancing, and altering the mode of communication with customers to digital forms. The healthcare activities that were compromised during the pandemic include vaccination, medical treatment of sick animals, and prophylactic treatment.

However, rising government initiatives and new product launches played a key role in supporting the market growth. For instance, in March 2021, Federal Service for Veterinary and Phytosanitary Surveillance (Russia) registered the world's first animal vaccine against the Covid-19. Similarly, in June 2021, The UK government has announced the establishment of the UK Animal Vaccine Manufacturing and Innovation Centre in Surrey to speed up the development of livestock vaccines and reduce the spread of viral illnesses such as coronavirus. As a result of the rising number of COVID-19 infection cases in animals, research initiatives adopted by the key players, and government support, the animal vaccines industry will be able to expand rapidly. 

June 2022

As COVID-19 cases rise across India, the Centre launched the nation’s first animal vaccine — Ancovax — against SARS-CoV-2 virus. Ancovax — a COVID-19 vaccine for animals like dogs, lions, leopards, mice and rabbits — contains an inactivated SARS-CoV-2 (Delta) antigen capable of neutralizing both Delta and Omicron variants. Developed by the Indian Council of Agricultural Research-National Research Centre on Equines (ICAR-NRCE), this vaccine is one of the six vaccines indigenously produced by the Indian institute.

Market Dynamics:

Market Drivers

  • Rising zoonotic and chronic diseases in animals

    • Increasing zoonotic and chronic diseases among animals affect human interests widely. According to the Centers for Disease Control and Prevention (CDC), eight types of zoonotic diseases can be transmitted from animals to humans, including zoonotic influenza, Lyme disease, salmonellosis, brucellosis, severe acute respiratory syndrome, the Middle East respiratory syndrome, West Nile virus, rabies, and plague. Zoonotic infections can readily be transmitted to humans working in close contact with animals.

    • As per the World Health Organization (WHO) statistics, approximately 59,000 human deaths occur each year by rabies virus across the globe. The spread of such diseases is contributing to the rising demand for animal vaccines. Furthermore, one of the main reasons for the growing number of chronic diseases is the increasing life expectancy of pets due to the developed healthcare facilities and good nutrition.

  • Increasing emphasis on animal healthcare and vaccination

  • Increased consumption of Animal-based products

Market Restraints

  • Stringent regulatory guidelines and high storage costs associated with animal vaccines

    • Stringent regulatory guidelines on vaccine approval are major challenges in the market's growth. United States Department of Agriculture (USDA), Food and Drug Administration (FDA), are some of the major regulatory bodies reviewing and approving veterinary medicines in the US. While in the European Union, the European Medicines Agency (EMA) is the leading body involved in the approval of animal health-related products. All authorized vaccines are required to undergo a stringent regulatory approval process before they are marketed.

    • These approvals help to ensure that animal vaccines meet the required safety, quality, and efficacy. Vaccine efficacy and safety are monitored after they are approved and used in animals through a surveillance system in which any adverse occurrences can be reported to the vaccine's Market Authorisation Holder (MAH). Hence, the high storage cost of vaccines and stringent regulatory guidelines on vaccine approval is restraining animal vaccines market growth.

Market Opportunities

  • Rising investments in veterinary hospitals to improve animal health

    • The rise in spending on veterinary hospitals to ensure quality services provides a lucrative growth opportunity for the market. The increasing adoption of farm and companion animals globally has driven animal hospitals and clinics by the increasing per capita income, the spending of pet and livestock owners on the wellbeing of the animals have increased considerably in the recent past. As per the American Pet Products Association, in 2020, it was estimated that around USD 103.6 billion was spent on pets in the US, up from USD 97.1 billion in 2019.

    • Moreover, the future of animal health depends on technological advancement in animal health and superior patient care, the development of new products, and the collaborative development of vaccines. Pet owners are spending a higher amount to seek the best available treatments for their companions. This has led to an increase in investment in veterinary hospitals. In addition, governments across the globe are spending a significant amount on veterinary hospitals.

Value Chain Analysis/Technology Analysis/Regulatory Implications

  • The global animal vaccines market is growing steadily and is expected to continue growing gradually at a significant rate in the near future. This is due to the growing contribution of existing players to make the service more effective. The value chain analysis for the animal vaccines market comprises four major components: customer acquisition, service customization, customer purchase support, customer fulfillment, and post-purchase support.

September 2022

Merck Animal Health has announced the domestic launch of the first oral Bordetella bronchiseptica and canine parainfluenza virus vaccine with mucosal protection and easy oral administration. The Nobivac Intra-Trac Oral BbPi formulation is expected to become available for veterinary clinics to purchase in the United States in fall 2022.

The vaccine has been shown to be effective for vaccination of healthy dogs aged 7 weeks or older against canine parainfluenza virus and Bordetella bronchiseptica. The product is thimerosal-free and contains no preservatives, and it affords veterinarians and support staff the ability to offer clients dual protection against 2 major respiratory pathogens while providing a better vaccination experience for dogs.Segment OverviewThe global animal vaccines market is segmented into type, technology, and region.By Type

  • Porcine Vaccines

    • Porcine vaccines contain antigens from viruses, bacteria, bacterial toxins, or parasites. These vaccines are given to pigs generally by injection to stimulate an immune response, which protects against natural infection with the organism from which the vaccine was derived. Porcine vaccines commonly used on pig farms around the globe include erysipelas, parvovirus infection (SMEDI syndrome), clostridial dysentery of piglets, E. coli diarrhea, enzootic pneumonia caused by Mycoplasma hyopneumoniae, necrotic pleuropneumonia caused by Actinobacillus pleuropneumoniae, and atrophic rhinitis caused by toxigenic Pasteurella multocida. These vaccines can be inactivated, containing only killed organisms, or live, containing living organisms.

  • Poultry Vaccines

    • Poultry vaccines increase disease defense power in the poultry body. There are various types of poultry vaccines, including live vaccines, attenuated vaccines, and killed vaccines. Some of the vaccines used in the poultry farms are the BCRDV vaccine, RDV vaccine, Gumboro live vaccines, Gumboro dead vaccines, and cholera vaccine. Boehringer Ingelheim Animal Health offers a Volvac Line of poultry vaccines, protection against respiratory, immune, and enteric diseases.

  • Livestock Vaccines

    • Vaccines help in the reduction of losses when used correctly to prevent disease in livestock animals. Potential benefits of the vaccine include improved animal welfare and public health. The presence of a few bacterial, viral, and protozoan-borne diseases severely impacts the productivity of livestock. Timely vaccination prevents the risk of infection as well as affects a farmer's income through livestock rearing.

  • Companion Animal Vaccines

    • Companion animals suffer from a range of infectious diseases.  The diseases controlled by vaccination in these animals include infectious canine hepatitis, leptospirosis, parvovirus, feline infectious enteritis, influenza, tetanus, viral arteritis, and others. Merck Animal Health offers vaccines for companion animals. Nobivac is an extensive range of vaccines that protect dogs, cats, and rabbits against many different diseases.

  • Aquacultutre Vaccines

    • Aquaculture vaccines play an important role in large-scale commercial fish farming. Most of the vaccines for aquaculture to date are protective against bacterial pathogens and can be administered either orally or by injection. The most common aquaculture vaccine types include live attenuated bacterins, subunit vaccines, and toxoids. MSD Animal Health company offers AQUAVAC ERM, an inactivated water-based immersion vaccine for protection against Enteric Redmouth Disease.

By Technology

  • Live Attenuated Vaccines

    • Live attenuated vaccines are derived from disease-causing pathogens such as viruses or bacteria that have been weakened under laboratory conditions so that they are not able to cause disease itself but can produce a robust immune response. These vaccines create a more prolonged and robust immune response. Examples of live attenuated vaccines include most canine distemper virus vaccines and all canine parvovirus and adenovirus-2 vaccines.

  • Inactivated Vaccines

    • Inactivated vaccines, also known as killed vaccines, contain a completely inactivated pathogen, which is no longer infectious. These vaccines often contain an adjuvant, which is a compound added to help improve the protective immune response. These vaccines are generally considered very safe. Examples of inactivated vaccines are all canine rabies vaccines, all canine influenza vaccines, and others.

  • Toxoid Vaccines

    • Toxoid vaccines are based on inactivated toxins produced by pathogens that have been sufficiently attenuated yet can induce a humoral immune response. These vaccines tend not to have a duration of immunity comparable to attenuated viral vaccines. In these types of vaccines, booster doses may be required multiple times in a single year. An example of a toxoid vaccine is the Crotalus atrox toxoid vaccine.

  • Recombinant Vaccines

    • Recombinant technology is relatively new to veterinary vaccines. Recombinant vaccines combine safety, potency, purity, and efficacy into one vaccine. Licensed recombinant vaccines in animal vaccines include those protecting against Lyme disease, canine distemper, pseudorabies, rabies, Newcastle disease, and a strain of avian influenza.

  • Others

    • Other’s segment involves subunit vaccines, toxoid vaccines, conjugate vaccines, and DNA vaccines. Subunit vaccines contain fragments of protein or polysaccharides from the pathogen that are noninfectious. Toxoid vaccines are made by purifying the bacterial exotoxin. DNA vaccine uses a gene from a virus or bacteria to stimulate the immune system. It has several advantages, such as simplicity of manufacture, biological stability, cost-effectiveness, and safety.

  • August 2022

  • Nagaland’s animal husbandry and veterinary services department, under the aegis of the Nagaland Livestock Development Board (NLDB), officially launched the second phase of the National Animal Disease Control Programme for vaccination of Foot and Mouth Disease (NADCP). The NADCP envisages control of foot and mouth disease (FMD) and brucellosis diseases in livestock by 2025 and freedom status by 2030. The mission is to encourage farmers to allow their livestock to get vaccinated against the FMD.

GLOBAL Animal Vaccines MARKET SHARE (%), BY Region, 2020Global Animal Vaccines Market Share By Region 2020Source: MRFR AnalysisRegional AnalysisThe global animal vaccines market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East, & Africa.Americas:

  • Americas dominated the global animal vaccine market in 2020 due to the rising prevalence of animal diseases and the rise in pet ownership in the region. The high number of veterinary clinics in the region also boosts the growth of the market. There is an increasing prevalence of animal diseases such as foot & mouth disease, canine parvovirus, and reproductive & respiratory syndrome.

  • The number of pet dogs in the US increased from 140 million in 2019 to 149 million in 2020, representing approximately 7% growth. Similarly, according to the statistics published by the Canadian Veterinary Medical Association in 2020, about 12,921 veterinarians were present in Canada. This has led to an increasing number of pets in the region.


  • The European region held a significant share in the market owing to the high population of companion animals and rising research and development investment. According to the Industrial Association of Pet Care Producers, there are around 34 million pets in the UK, including dogs, cats, small mammals, and birds. Moreover, PFMA estimated that 59% of the households in the UK have at least one pet. Rising research and development investment has also resulted in the development of novel and more sophisticated technologies.


  • Asia-Pacific is expected to exhibit the highest CAGR during the forecast period. This is due to several factors such as increasing awareness about animal health, a rise in the livestock population, and the increasing prevalence of animal diseases in the region. There is increasing awareness about animal health in the Asia-Pacific region. For instance, according to the report published by Pet Fair Asia, the total number of pet dogs and cats in China reached 99.15 million, with pet owners spending 29 billion US dollars in 2019. The increasing prevalence of animal diseases such as foot and mouth disease and avian influenza boosts the market growth in the region.

Middle East and Africa:

  • The Middle East & Africa region is estimated to show staggering growth due to limited access and healthcare affordability. The common zoonotic disease diagnosed in this region is Rift Valley fever. Hence, emphasis is being put on promoting animal health in the region and improving healthcare services for companion animals.

May 2022

Mazen, an animal health company developing novel oral vaccines, has closed its Series A financing round of over $11M. The round was led by Fall Line Capital and joined by all the seed investors, including Next Level Ventures, Kent Corporation, Ag Startup Engine, Ag Ventures Alliance, ISAV and Summit Ag. Mazen offers a transformative vaccine technology where the animals don't even know they are being vaccinated.Competitive LandscapeThe key players operating in the global animal vaccines market include Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Ceva Santé Animale (France), Merck & Co., Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Phibro Animal Health Corporation (US), Hipra (Spain), Biogénesis Bagó S.A.(Argentina), Neogen Corporation (US). To expand their reach and optimize their operational costs, the major players have adopted the strategy of obtaining regulatory authorizations from government agencies for their products, as well as collaborative partnerships and new product launches to gain a substantial market share.List of Key Companies Covered in this report:

  • Boehringer Ingelheim International GmbH (Germany)

  • Zoetis Inc. (US)

  • Ceva SantĂ© Animale (France)

  • Merck & Co., Inc. (US)

  • Elanco Animal Health Incorporated (US)

  • Virbac (France)

  • Phibro Animal Health Corporation (US)

  • Hipra (Spain)

  • BiogĂ©nesis BagĂł S.A.(Argentina)

  • Neogen Corporation (US)

Recent Developments

  • In September 2021, Virbac entered into a collaboration agreement with Jectas Innovators to develop animal health vaccines.

  • In February 2021, Virbac entered into an international commercial licensing agreement with Algenex SL to develop and commercialize a CrisBio-based vaccine in a major swine indication.

  • In October 2021, Boehringer Ingelheim International GmbH announced an investment of USD 115.98 million towards the expansion of its veterinary vaccine capacity in Lyon-Jonage, France. The capacity expansion is aimed towards helping governments and public health organizations in the management of emerging and transboundary diseases.

  • In February 2021, CevaSantĂ© Animale and INRAE entered into a first framework agreement, which is aimed towards the consolidation of their collaboration in veterinary health. In addition to several other forms of collaboration, it also includes the exchange of lab personnel and testing of vaccines and anti-infective treatments.

  • In August 2020, Elanco Animal Health Incorporated completed the acquisition of the animal health business unit of Bayer AG

Report Overview:

  • The study covers the existing short-term and long-term market effects, helping decision-makers draft short-term and long-term plans for businesses by region. The report covers major regions in the Americas, Europe, Asia-Pacific, and Middle East & Africa. The report analyzes market drivers, restraints, opportunities, challenges, Porter's Five Forces, Value Chain, and impact of COVID-19 on the market.

Study Objectives

  • To provide a comprehensive analysis of the global animal vaccines market and its sub-segments, thereby providing a detailed structure of the industry

  • To provide detailed insights into factors driving and restraining the growth of the animal vaccines market

  • To estimate the market size of the animal vaccines market where 2018 to 2019 would be the historical period, 2020 shall be the base year, and 2021 to 2027 will be the forecast period for the study

  • To provide strategic profiling of key companies (manufacturers and distributors) present across the countries, and comprehensively analyze their competitiveness/competitive landscape in this market

  • To provide a value chain analysis for the animal vaccines market.

Market Segmentation: Global Animal Vaccines Market, by Type

  • Porcine Vaccines

  • Poultry Vaccines

  • Livestock Vaccines

  • Companion Animal Vaccines

  • Aquacultutre vaccines

Global Animal Vaccines Market, by Technology

  • Live attenuated vaccines

  • Inactivated vaccines

  • Toxoid vaccines

  • Recombinant vaccines

  • Other

  • Others

Global Animal Vaccines Market, by Region

  • Americas

    • North America

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • France

      • UK

      • Italy

      • Spain

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East and Africa

    • Middle East

    • Africa

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 15,250.5 Million
  CAGR   7.50%
  Base Year   2020
  Forecast Period   2021–2030
  Historical Data   2019
  Forecast Units    Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Technology and Region
  Geographies Covered   Americas, Europe, Asia-Pacific, and Middle East and Africa
  Key Vendors   Boehringer Ingelheim International GmbH (Germany) • Zoetis Inc. (US) • Ceva SantĂ© Animale (France) • Merck & Co., Inc. (US) • Elanco Animal Health Incorporated (US) • Virbac (France) • Phibro Animal Health Corporation (US) • Hipra (Spain) • BiogĂ©nesis BagĂł S.A.(Argentina) • Neogen Corporation (US)
  Key Market Opportunities   Rising investments in veterinary hospitals to improve animal health
  Key Market Drivers   Rising zoonotic and chronic diseases in animals • Increasing emphasis on animal healthcare and vaccination

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The global veterinary/animal vaccines market is expected to reach a valuation of USD 15,250.5 Million by 2030.

The global veterinary/animal vaccines market is expected to exhibit a solid 7.50% CAGR over the forecast period from 2020 to 2030.

The growing awareness about animal health among pet as well as livestock owners is the major driver for the market.

The Americas is likely to be the leading regional market for veterinary/animal vaccines due to the widespread awareness in the region about animal health.

Leading players in the veterinary/animal vaccine market include Boehringer Ingelheim, Virbac, Elanco, MSD & Co., Ceva, and Zoetis, among others.